Pancreatic Comprehensive Assessment Panel
- $4,802.48
- $1,384.95
- Save: 71.16%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Amylase
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Ca 125
Also known as: CA 199, Carbohydrate Antigen 19-9
Ca 19-9
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Absolute Band Neutrophils (Only Reported If Detected)
Absolute Basophils
Absolute Blasts (Only Reported If Detected)
Absolute Eosinophils
Absolute Lymphocytes
Absolute Metamyelocytes (Only Reported If Detected)
Absolute Monocytes
Absolute Myelocytes (Only Reported If Detected)
Absolute Neutrophils
Absolute Nucleated Rbc (Only Reported If Detected)
Absolute Promyelocytes (Only Reported If Detected)
Band Neutrophils (Only Reported If Detected)
Basophils
Blasts (Only Reported If Detected)
Eosinophils
Hematocrit
Hemoglobin
Lymphocytes
MCH
MCHC
MCV
Metamyelocytes (Only Reported If Detected)
Monocytes
MPV
Myelocytes (Only Reported If Detected)
Neutrophils
Nucleated Rbc (Only Reported If Detected)
Platelet Count
Promyelocytes (Only Reported If Detected)
RDW
Reactive Lymphocytes (Only Reported If Detected)
Red Blood Cell Count
White Blood Cell Count
Also known as: Carcinoembryonic Antigen
Cea
CHROMOGRANIN A, LC/MS/MS
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Gastrin
Glucagon
Also known as: Insulin (fasting)
Insulin
Also known as: LPS
Lipase
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
LDL/HDL Ratio
Non HDL Cholesterol
Triglycerides
Also known as: Pancreatic Elastase1
Pancreatic Elastase-1
PANCREATIC POLYPEPTIDE,
Proinsulin
The Pancreatic Comprehensive Assessment Panel panel contains 16 tests with 73 biomarkers .
Overview of the Pancreatic Comprehensive Assessment Panel
The Pancreatic Comprehensive Assessment Panel is a robust diagnostic tool designed to evaluate the full spectrum of pancreatic health, including exocrine and endocrine function, tumor marker activity, and neuroendocrine hormone secretion. It integrates digestive enzyme analysis, metabolic and hematologic profiles, cancer surveillance markers, and specialized neuroendocrine hormones. This panel is particularly useful for detecting both benign and malignant pancreatic disorders, assessing hormone-secreting tumors, evaluating pancreatic enzyme sufficiency, and providing insights into systemic effects related to pancreatic disease. Its comprehensive nature allows clinicians to investigate a wide range of symptoms and conditions with one coordinated panel.
When and Why the Pancreatic Comprehensive Assessment Panel May Be Ordered
This panel may be ordered when a patient presents with symptoms suggestive of pancreatic dysfunction or disease, such as persistent abdominal pain, unexplained weight loss, jaundice, chronic diarrhea, steatorrhea, new-onset diabetes, or recurrent hypoglycemia. It is also indicated for individuals with a personal or family history of pancreatic cancer, pancreatitis, or genetic syndromes such as MEN1 (Multiple Endocrine Neoplasia type 1), which predispose to neuroendocrine tumors. Additionally, this panel is useful in monitoring patients undergoing treatment for pancreatic cancer, functional neuroendocrine tumors, or chronic pancreatic insufficiency, and in evaluating unexplained gastrointestinal or metabolic symptoms.
What the Pancreatic Comprehensive Assessment Panel Checks For
The panel evaluates three critical domains of pancreatic health: enzyme production and exocrine function, tumor marker activity, and endocrine hormone regulation. Each marker provides valuable information that helps clinicians understand the pancreas's structure, secretory function, and involvement in malignancy or systemic disease.
Exocrine Function and Digestive Enzymes
Markers like amylase, lipase, and pancreatic elastase-1 assess the digestive role of the pancreas. Elevated amylase and lipase are typically associated with acute pancreatic inflammation, while low pancreatic elastase-1 is a hallmark of chronic exocrine insufficiency.
Endocrine Hormones and Neuroendocrine Activity
Hormones such as insulin, proinsulin, glucagon, pancreatic polypeptide, gastrin, and vasoactive intestinal polypeptide (VIP) reflect the activity of islet and neuroendocrine cells. Abnormal elevations of these hormones are associated with functional pancreatic neuroendocrine tumors (PanNETs), each producing a distinct clinical syndrome.
Tumor Markers and Oncologic Surveillance
CA 19-9, CEA, CA 125, and chromogranin A are tumor markers associated with pancreatic adenocarcinoma and neuroendocrine tumors. CA 19-9 is the most specific for pancreatic ductal cancer, while CEA and CA 125 provide supportive data for cancer detection and progression. Chromogranin A is an essential marker for neuroendocrine tumor activity.
Metabolic and Hematologic Panels
The comprehensive metabolic panel (CMP), complete blood count (CBC), and lipid panel assess systemic impacts, including liver function, nutritional status, blood sugar control, anemia, infection, and lipid abnormalities. These are often altered in pancreatic diseases and related systemic conditions.
Conditions and Diseases the Pancreatic Comprehensive Assessment Panel Can Detect
This panel allows for the detection and evaluation of a wide range of conditions, including acute and chronic pancreatitis, pancreatic cancer, pancreatic exocrine insufficiency, pancreatic neuroendocrine tumors (PanNETs), and metabolic disorders linked to pancreatic dysfunction.
Acute Pancreatitis
Acute pancreatitis is an inflammatory condition often triggered by gallstones, alcohol, or hypertriglyceridemia. It presents with sudden abdominal pain, nausea, and elevated amylase and lipase. This panel confirms the diagnosis and evaluates metabolic disturbances, such as elevated glucose or liver enzymes, through the CMP.
Chronic Pancreatitis
Chronic inflammation leads to progressive destruction of pancreatic tissue, causing digestive enzyme deficiency and diabetes. Low pancreatic elastase-1 indicates exocrine insufficiency, while mild elevations in amylase or lipase may persist. The CMP, lipid panel, and CBC help assess systemic impact and complications.
Pancreatic Cancer
Pancreatic ductal adenocarcinoma is a deadly cancer with few early signs. CA 19-9 is a sensitive tumor marker for this cancer, and CEA and CA 125 may also be elevated. The CBC and CMP help assess the disease burden and treatment tolerance. This panel provides a comprehensive tool for early detection and post-treatment surveillance.
Functional Pancreatic Neuroendocrine Tumors (PanNETs)
PanNETs are rare tumors that secrete hormones like insulin, glucagon, gastrin, VIP, or pancreatic polypeptide. These tumors can cause severe endocrine syndromes:
-
Insulinoma causes hypoglycemia, confirmed by elevated insulin and proinsulin during low glucose levels.
-
Gastrinoma leads to Zollinger-Ellison syndrome, marked by excessive gastrin and gastric acid production, causing ulcers and diarrhea.
-
Glucagonoma produces glucagon, causing diabetes, weight loss, and skin rashes.
-
VIPoma secretes VIP, causing profuse watery diarrhea, hypokalemia, and metabolic acidosis.
-
PPoma is often clinically silent but detectable via elevated pancreatic polypeptide levels.
Pancreatic Exocrine Insufficiency
This condition occurs when digestive enzyme output falls below normal, usually from chronic pancreatitis, cystic fibrosis, or advanced pancreatic cancer. Low pancreatic elastase-1, along with abnormal CMP and CBC values, supports the diagnosis and guides enzyme replacement therapy.
Metabolic and Nutritional Disorders
Pancreatic dysfunction often disrupts glucose metabolism and lipid levels. Elevated glucose may suggest diabetes, while abnormal lipids (especially triglycerides) are a risk factor for pancreatitis. The CMP and lipid panel help manage these complications.
How a Healthcare Professional Uses the Pancreatic Comprehensive Assessment Panel Results
Acute Pancreatitis
Elevated amylase and lipase confirm diagnosis, and the CMP is used to monitor electrolyte imbalances and kidney function. CBC provides inflammatory markers such as leukocytosis. These values guide hospitalization, fluid management, and imaging decisions.
Chronic Pancreatitis
Low pancreatic elastase-1 and enzyme patterns confirm exocrine insufficiency. Ongoing CMP and CBC monitoring help manage nutritional deficits, glucose levels, and systemic complications. This guides the use of enzyme supplements and dietary interventions.
Pancreatic Cancer
Tumor marker trends (especially CA 19-9) are used to support diagnosis, monitor response to chemotherapy, and detect recurrence. Elevated CEA or CA 125 further supports malignancy, while chromogranin A can detect neuroendocrine variants. CBC and CMP evaluate general health and organ function.
Functional PanNETs
Each hormone marker helps identify the specific tumor type. For instance, persistently high insulin and proinsulin levels during hypoglycemia confirm insulinoma. Elevated gastrin, glucagon, VIP, or pancreatic polypeptide identifies other PanNET subtypes. Chromogranin A supports the diagnosis and helps track tumor burden. These markers are crucial for diagnosis, imaging decisions, surgical planning, and post-treatment monitoring.
Pancreatic Exocrine Insufficiency
A low pancreatic elastase-1 level confirms the need for enzyme replacement therapy. Rechecking levels and monitoring symptoms helps optimize dosing. The CMP and CBC identify malnutrition and anemia, guiding supplemental therapy.
Metabolic Disorders
Abnormal glucose and lipid levels prompt further metabolic evaluation. Elevated fasting glucose may indicate diabetes secondary to pancreatic dysfunction, while high triglycerides increase pancreatitis risk. These values inform treatment with diet, medications, or insulin.
Conclusion
The Pancreatic Comprehensive Assessment Panel is a powerful diagnostic and monitoring resource that combines tumor markers, enzyme testing, hormone profiling, and metabolic screening into a single, clinically actionable panel. It provides a complete picture of pancreatic health and function, allowing early detection of malignancy, diagnosis of neuroendocrine tumors, identification of enzyme insufficiency, and management of metabolic complications. This panel supports both initial diagnostic workups and long-term surveillance in patients with complex pancreatic conditions, ultimately improving outcomes through timely and targeted interventions.